Buy NVCR by May 13, 2026.

Faster than expected FDA approval for NVCR shows the need. Even with the rally, $1.5bb cap is far too low. Two months additional life is meaningful. Bloomberg) -- Novocure shares gain as much as 34% in premarket trading on Thursday after the oncology company announced the US FDA approved its wearable medical device Optune Pax for treating locally advanced pancreatic cancer when used with gemcitabine and nab-paclitaxel chemotherapy. Analysts note that the approval came in earlier than expected.